Sermorelin Protocol

Evidence Level: Emerging Evidence

Human and/or animal research exists and is accumulating, but the evidence base is not yet as extensive as an approved medicine.

Human evidence: Older FDA-approved-brand trial data (pediatric GH deficiency, diagnostic testing) plus more recent compounded-use anecdotal literature.

Animal evidence: Foundational GHRH-fragment activity studies from the 1980s.

Introduction & Mechanism of Action

GHRH(1-29) analog historically studied diagnostically and therapeutically for GH-stimulation research.

The original, shortest fragment of GHRH shown to retain full biological activity; historically had FDA approval (brand since discontinued) for diagnostic GH-stimulation testing and pediatric GH-deficiency treatment.

Receptors/targets: GHRH receptor

Areas of Research Interest

• GH-stimulation research
• Endocrine-testing studies

Benefits Reported in Research

• GH-stimulation research
• Endocrine-testing studies

Reported Research Dosing Range

The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.

Reported range: 200–500 mcg

Reported frequency: 1× daily, subcutaneous

Reported cycle duration: 12–26 weeks

Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.

Research Reference Data

Published research on Sermorelin reports administration at 200–500 mcg via subcutaneous route. The table below cites that published research — it is not an individualized instruction.

Reconstitution Reference

Published research protocols reconstitute a 5 mg vial with 2 mL bacteriostatic water, yielding a concentration of 2.50 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.

Research Protocol Timeline

A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.

Dilution Guide

Reconstitute with 2 mL bacteriostatic water

Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.

Handling Guide

General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.

Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.

Storage

Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.

Monitoring

Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.

Side Effects

• Flushing
• Headache
• Injection-site reaction

Contraindications

• Active malignancy
• Pregnancy
• Pituitary tumor or history of pituitary surgery/radiation

Drug interactions

• Not extensively characterized for modern compounded use — older approved-brand labeling had a narrower interaction list

Safety

• Injection-site reactions
• Compounded (non-branded) supply is not FDA regulated and quality can vary by source

Original approved brand is discontinued; current compounded supply is not FDA-approved and quality can vary by pharmacy.

Expected Results & Comparison

Sermorelin has the longest historical human-use track record of the GHRH analogs in this catalog (as a formerly branded, FDA-approved diagnostic and pediatric therapy), even though its original brand is discontinued and current supply is compounded rather than FDA-regulated.

References

Continue